Supplementary Figure S2 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma

Supplementary Figure S2 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma

<p>Figure S2: Features of glioblastoma models used to assess therapeutic potential of EdU. The features in red are less than desirable, blue are moderately desirable, and green are ideal. As such, the compounds were tested on multiple cell culture platforms to supplement the weaknesses of indi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Humeyra Kaanoglu (21903844) (author)
Weitere Verfasser:	Adebimpe Adefolaju (21903847) (author), Casey Fraley (21903850) (author), Mariah Shobande (21903853) (author), Rajaneekar Dasari (21903856) (author), Breanna Mann (21903859) (author), Noah Bell (21903862) (author), Stephen T. Keir (18724623) (author), Dominique Higgins (21903865) (author), David E. Kram (15110825) (author), Shawn D. Hingtgen (21903868) (author), Aziz Sancar (21903871) (author), Andrew B. Satterlee (21903874) (author)
Veröffentlicht:	2025
Schlagworte:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Clinical Research and Trials Methods and Technology CNS Cancers Gliomas, Glioblastomas Dna Damage And Repair DNA damage Precision Medicine Preclinical Models Small Molecule Agents Translational Research
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Supplementary Figure S1 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
von: Humeyra Kaanoglu (21903844)
Veröffentlicht: (2025)

Supplementary Figure S3 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
von: Humeyra Kaanoglu (21903844)
Veröffentlicht: (2025)

Supplementary Figure S4 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
von: Humeyra Kaanoglu (21903844)
Veröffentlicht: (2025)

Supplementary Figure S5 from Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma
von: Humeyra Kaanoglu (21903844)
Veröffentlicht: (2025)

Supplementary Table S1 from The Spectrum of IDH- and H3-Wildtype High-Grade Glioma Subgroups Occurring across Teenage and Young Adult Patient Populations
von: Rita Pereira (21902867)
Veröffentlicht: (2025)

Supplementary Table S2 from The Spectrum of IDH- and H3-Wildtype High-Grade Glioma Subgroups Occurring across Teenage and Young Adult Patient Populations
von: Rita Pereira (21902867)
Veröffentlicht: (2025)

Supplementary Table S3 from The Spectrum of IDH- and H3-Wildtype High-Grade Glioma Subgroups Occurring across Teenage and Young Adult Patient Populations
von: Rita Pereira (21902867)
Veröffentlicht: (2025)

Supplementary Table S4 from The Spectrum of IDH- and H3-Wildtype High-Grade Glioma Subgroups Occurring across Teenage and Young Adult Patient Populations
von: Rita Pereira (21902867)
Veröffentlicht: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
von: Sied Kebir (15048732)
Veröffentlicht: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
von: Sied Kebir (15048732)
Veröffentlicht: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
von: Sied Kebir (15048732)
Veröffentlicht: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
von: Sied Kebir (15048732)
Veröffentlicht: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
von: Sied Kebir (15048732)
Veröffentlicht: (2025)

Supplementary Figure 1 from Current Status and Challenges of Vaccination Therapy for Glioblastoma
von: Hamed Hosseinalizadeh (15062761)
Veröffentlicht: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
von: Qingsheng Xu (17078830)
Veröffentlicht: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
von: Qingsheng Xu (17078830)
Veröffentlicht: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
von: Bachchu Lal (17141949)
Veröffentlicht: (2025)

Figure 1 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
von: Diana M. Carvalho (5608127)
Veröffentlicht: (2025)

Figure 2 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
von: Diana M. Carvalho (5608127)
Veröffentlicht: (2025)

Figure 3 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
von: Diana M. Carvalho (5608127)
Veröffentlicht: (2025)

Figure 4 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
von: Diana M. Carvalho (5608127)
Veröffentlicht: (2025)

Figure 5 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
von: Diana M. Carvalho (5608127)
Veröffentlicht: (2025)

Table 1 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
von: Diana M. Carvalho (5608127)
Veröffentlicht: (2025)

Table 2 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
von: Diana M. Carvalho (5608127)
Veröffentlicht: (2025)

Supplementary Figure S1 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Figure S2 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Figure S3 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Figure S4 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Figure S5 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Figure S6 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Figure S7 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Figure S8 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Table S1 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Table S2 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Table S3 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Table S4 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Table S5 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Table S6 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Table S7 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)

Supplementary Table S8 from Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype
von: Fleur M.G. Cornelissen (22761190)
Veröffentlicht: (2025)